| Year |
Citation |
Score |
| 2023 |
Jenkins KA, Park M, Pederzoli-Ribeil M, Eskiocak U, Johnson P, Guzman W, McLaughlin M, Moore-Lai D, O'Toole C, Liu Z, Nicholson B, Flesch V, Qiu H, Clackson T, O'Hagan RC, et al. XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer. Journal For Immunotherapy of Cancer. 11. PMID 38164757 DOI: 10.1136/jitc-2023-007785 |
0.526 |
|
| 2023 |
Patel E, Malkova NV, Crowe D, Pederzoli-Ribeil M, Fantini D, Fanny M, Madala HR, Jenkins KA, Yerov O, Greene J, Guzman W, O'Toole C, Taylor J, O'Donnell RK, Johnson P, et al. XTX301, a tumor-activated Interleukin-12 has the potential to widen the therapeutic index of IL-12 treatment for solid tumors as evidenced by pre-clinical studies. Molecular Cancer Therapeutics. PMID 38030380 DOI: 10.1158/1535-7163.MCT-23-0336 |
0.511 |
|
| 2022 |
Kuo YC, Kuo CF, Jenkins K, Hung AF, Chang WC, Park M, Aguilar B, Starr R, Hibbard J, Brown C, Williams JC. Antibody-based redirection of universal Fabrack-CAR T cells selectively kill antigen bearing tumor cells. Journal For Immunotherapy of Cancer. 10. PMID 35728874 DOI: 10.1136/jitc-2021-003752 |
0.563 |
|
| 2018 |
Karow M, Jenkins K, Park M, Johnson P, Gonzalez A, Flesch V, Miles T, Rodeck U, Williams JC. Pre-clinical assessment of rational design immuno-oncology biologics with improved therapeutic indices. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.E15096 |
0.47 |
|
| 2017 |
Herrmann A, Lahtz C, Nagao T, Song JY, Chan WC, Lee H, Yue C, Look T, Muelfarth R, Li W, Jenkins K, Williams J, Budde LE, Forman SJ, Kwak LW, et al. CTLA4 promotes Tyk2-STAT3 dependent B cell oncogenecity. Cancer Research. PMID 28716895 DOI: 10.1158/0008-5472.Can-16-0342 |
0.49 |
|
| Show low-probability matches. |